Gov't eyes to limit COVID-19 vaccine rollout to 3 to 4 brands | Inquirer News

Gov’t eyes to limit COVID-19 vaccine rollout to 3 to 4 brands

/ 03:08 PM January 29, 2022

MANILA, Philippines — The government may just use three to four COVID-19 vaccine brands in the future, the chairperson of the National Vaccination Operations Center (NVOC) said Saturday.

According to NVOC chair and Health Undersecretary Myrna Cabotaje, the country has too many portfolios of COVID-19 vaccines.

ADVERTISEMENT

“Hindi na po tayo bibili, sa aking pagkakaintindi, ng Sputnik vaccine. Alam naman natin na kailangan natin ilimit. Masyado nang marami tayong portfolio ng bakuna dahil sa preferences, so baka ilimit lang natin sa three or four vaccines in the future,” she said at the Laging Handa public briefing when asked about the procurement of Sputnik Light vaccines.

(Based on my knowledge, we will no longer procure Sputnik vaccines. We know we should limit the vaccine brands. We have too many vaccine portfolios, so maybe we should just limit this to three or four vaccines in the future.)

At present, the COVID-19 vaccines being used in the vaccination rollout are Pfizer, Moderna, Sinovac, Sputnik, Janssen, and AstraZeneca.

je
Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.

TAGS: coronavirus Philippines, COVID-19, COVID-19 Vaccine

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.